Central Nervous System Depressants

2

Review clinical trials related to Central Nervous System Depressants. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide. People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254. This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time. Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.

Participants needed: 500
Trial details
Age: 18-120Biological sex: AllType: ObservationalSponsor: National Institute of Mental Health (NIMH)Updated: Jun 29, 2026Locations: 1
Eligibility criteria

Signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and... [+3]

Unstable medical conditions in the opinion of the investigator that would preclu... [+3]

Status: Recruiting

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.

Participants needed: 2,400
Trial details
Phase: Phase 4Age: 60+Biological sex: AllType: InterventionalSponsor: Sunnybrook Health Sciences CentreUpdated: Dec 1, 2025Locations: 8
Eligibility criteria

Planned CABG (+/- valve, including off-pump) or valve replacement via sternotomy... [+1]

Lack of patient consent [+4]